Can a slower dose of this cancer drug ease harsh side effects?

NCT ID NCT06001762

Ongoing Symptom relief Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether gradually increasing the dose of abemaciclib (a targeted cancer drug) can reduce side effects like diarrhea and help patients stick with treatment. It involves 90 people with early-stage, hormone receptor-positive, HER2-negative breast cancer who are also taking standard hormone therapy. The goal is to see if this slower approach is better tolerated than the usual fixed dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib (a targeted cancer drug)
What this could lead to: If successful, this could lead to a better-tolerated way to take abemaciclib, reducing side effects like diarrhea and helping more patients complete their treatment.
What could go wrong: This is a small, early-phase trial (90 people) testing tolerability, not effectiveness. The dose-escalation strategy may still cause side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER EARLY-STAGE BREAST CANCER HIGH RISK BREAST CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Boston Medical Center

Boston, Massachusetts, 02118, United States
Dana-Farber Cancer Insitute at Londonderry Hospital

Londonderry, New Hampshire, 03053, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute at Foxborough

Foxborough, Massachusetts, 02035, United States
Dana-Farber Cancer Institute at Merrimack Valley

Methuen, Massachusetts, 01844, United States
Dana-Farber Cancer Institute at Milford

Milford, Massachusetts, 01757, United States
Dana-Farber Cancer Institute at South Shore

South Weymouth, Massachusetts, 02190, United States
Dana-Farber Cancer Institute at Steward St. Elizabeth's

Brighton, Massachusetts, 02135, United States
Eastern Maine Medical Center (Northern Light)

Brewer, Maine, 04412, United States
New England Cancer Specialists

Scarborough, Maine, 04074, United States
Stamford Hospital

Stamford, Connecticut, 06904, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.